Name: LY2109761
Brand: Selleck Chemicals
SKU: S2704
Availability: InStock
Rating: 5 (138 reviews)

Jump to

Quality Control

Batch: Purity: 99.99%

99.99

Products Often Used Together with LY2109761

Galunisertib (LY2157299)

It and Galunisertib target TGF-β receptor I and exhibit anti-tumor activity.

Related Targets	PKC ROCK Bcr-Abl
Other TGF-beta/Smad Inhibitors	SB431542 LDN-193189 Galunisertib (LY2157299) RepSox (E-616452) A-83-01 Vactosertib (TEW-7197) SRI-011381 (C381) SB-525334 LDN-193189 Dihydrochloride SIS3 Hydrochloride

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HepG2	Function Assay	10 μM	2 h		inhibits autophagy induction by galangin	25268046
PC-3	Function Assay	0.2/2/4 μM	24 h	DMSO	inhibits TGF-β1–induced Smad2 activation	22173053
PMOs	Function Assay	0.2/2/4 μM	24 h	DMSO	inhibits TGF-β1–induced Smad2 activation	22173053
PC-3	Growth Inhibition Assay	0.2/2 μM	24 h	DMSO	blocks the inhibition of cell proliferation produced by TGF-β1	22173053
PMOs	Growth Inhibition Assay	0.2/2 μM	24 h	DMSO	blocks the inhibition of cell proliferation produced by TGF-β1	22173053
U87MG	Growth Inhibition Assay	5/10 μM	2 h		enhances radiosensitivity	22006998
T98	Growth Inhibition Assay	5/10 μM	2 h		enhances radiosensitivity	22006998
U87MG	Apoptosis Assay	10 μM	2 h		enhances radiation-induced DNA damage and apoptosis rates	22006998
NMA-23	Apoptosis Assay	10 μM	2 h		enhances radiation-induced DNA damage and apoptosis rates	22006998
HLE	Function Assay	0.01-100 nM	48 h		inhibits the migration in a dose-dependent manner	20844878
HLF	Function Assay	0.01-100 nM	48 h		inhibits the migration in a dose-dependent manner	20844878
10A/HER2YVMA	Growth Inhibition Assay	0.1-0.5 μM	9 d		reduces the size, invasiveness and cell number of colonies	20383197
MC38	Growth Inhibition Assay	5 μM	5 d		inhibits cell growth in a time-dependent manner	19909744
U937	Growth Inhibition Assay	5-20 μM	24-72 h		inhibits cell growth slightly	18492113
HLE	Cytotoxity Assay	0.001-20 μM	48 h		induces cell cytotoxity in a dose-dependent manner	18318443
HLF	Cytotoxity Assay	0.001-20 μM	48 h		induces cell cytotoxity in a dose-dependent manner	18318443
Sf9	Function assay		1 hr		Inhibition of human His-tagged TGFbetaR1 T204D mutant expressed in Sf9 insect cells after 1 hr by HTRF assay, IC50 = 0.0037 μM.	29422332
Sf9	Function assay				Inhibition of TGFbeta type receptor 1 ALK5 (T204D) expressed in Sf9 cells, IC50 = 0.069 μM.	18314943
Mv1Lu-p3TP-Lux	Antiproliferative assay				Antiproliferative activity against mink Mv1Lu-p3TP-Lux cells by luciferase reporter assay, IC50 = 0.18 μM.	18314943
NIH3T3	Antiproliferative assay				Antiproliferative activity against mouse NIH3T3 cells by [3H]thymidine assay, IC50 = 0.21 μM.	18314943
Calu6	Function assay				Inhibition of TGFbeta type receptor 1 in orally dosed human Calu6 cells xenografted mouse by IVTI pharmacokinetic assay, EC50 = 0.236 μM.	18314943
T-cells	Function assay		1 hr		Inhibition of TGFbetaR1 in human primary T-cells assessed as TGFbeta-stimulated PSMAD phosphorylation preincubated for 1 hr followed by TGFbeta addition measured after 90 mins by Alpha screen assay, IC50 = 0.37 μM.	29422332
Mv1Lu	Function assay		1 hr		Inhibition of TGFbetaR1 in mink Mv1Lu cells assessed as TGFbeta-stimulated PSMAD2 phosphorylation preincubated for 1 hr followed by TGFbeta addition measured after 15 mins, IC50 = 0.75 μM.	29422332
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 9 mg/mL (20.38 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	441.52	Formula	C₂₆H₂₇N₅O₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	700874-71-1	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	C1CC2=C(C(=NN2C1)C3=CC=CC=N3)C4=C5C=CC(=CC5=NC=C4)OCCN6CCOCC6

Mechanism of Action

Targets/IC₅₀/Ki	TβRI (Cell-free assay) 38 nM(Ki) TβRII (Cell-free assay) 300 nM(Ki)
In vitro	LY2109761 treatment induces a dose-dependent low-anchorage growth inhibition of L3.6pl/GLT cells, leading to ~33% or 73% inhibition at 2 μM and 20 μM, respectively, which can be strongly enhanced when in combination index value of 0.36581. Blocking TβRI/II kinase activity with this compound completely suppresses both the basal and TGF-β1-stimulated migration and invasion of L3.6pl/GLT cells, significantly enhances the detachment-induced apoptosis by 26% at 8 hours treatment, and completely suppresses TGF-β–induced Smad2 phosphorylation. This chemical treatment at 1 nM is sufficient to significantly block the migration and invasion but not adhesion of hepatocellular carcinoma cells by increasing E-cadherin expression. It pretreatment enhances radiosensitivity of glioblastoma cells via TGF-β signaling blockage. This compound reduces the self-renewal and proliferation of GBM-derived cancer stem–like cells (CSLC), which can be significantly enhanced when combined with radiation.
In vivo	Administration of LY2109761 (50 mg/kg) alone or in combination significantly reduces the tumor volume by ~70% and ~90%, respectively, prolongs the survival with the median survival duration of 45.0 days and 77.5 days, respectively, and reduces spontaneous abdominal metastases in the L3.6pl/GLT Xenograft mice model. In consistent with the in vitro effect, administration of this compound alone or in combination with radiation, markedly inhibits tumor growth in the orthotopical CSLC glioblastoma model by 43.4% and 76.3%, respectively, decreases tumor invasion and tumor microvessel density, and significantly enhances radiation-induced tumor growth delay in the U87MG xenograft mice model.
References	[1] https://pubmed.ncbi.nlm.nih.gov/18413796/ [2] https://pubmed.ncbi.nlm.nih.gov/18318443/ [3] https://pubmed.ncbi.nlm.nih.gov/22006998/

Applications

Methods	Biomarkers	Images	PMID
Western blot	p-Smad2 / Smad E-cadherin β-catenin / MMP-9 / MMP-2 / nm23 / uPA / COX-2 CDK2 / CDK4 / Cyclin D1 / p-Rb		29416682

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

LY2109761 TGF-beta/Smad inhibitor

Chemical Structure

Molecular Weight: 441.52